Crystal structure of enoyl-acyl carrier protein reductase (FabK) from Streptococcus pneumoniae reveals the binding mode of an inhibitor

Protein Science

Volumn 17, Issue 4, 2008, Pages 691-699

  Saito, Jun ^a   Yamada, Mototsugu ^a   Watanabe, Takashi ^a   Iida, Maiko ^a   Kitagawa, Hideo ^a   Takahata, Sho ^a   Ozawa, Tomohiro ^a   Takeuchi, Yasuo ^a   Ohsawa, Fukuichi ^a  

^a MEIJI SEIKA KAISHA LTD   (Japan)

Author keywords

Antibiotics; Enoyl acyl carrier protein reductase; FabK; Fatty acid biosynthesis; Inhibitor

Indexed keywords

2 NITROPROPANE; COENZYME A; DIOXYGENASE; ENOYL ACYL CARRIER PROTEIN REDUCTASE (NADH); FATTY ACID SYNTHASE; FLAVINE MONONUCLEOTIDE; HISTONE; IMIDAZOLE DERIVATIVE; PHENYLIMIDAZOLE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE; THIAZOLE; TRIOSEPHOSPHATE ISOMERASE; UNCLASSIFIED DRUG;

ARTICLE; CATALYSIS; DRUG PROTEIN BINDING; DRUG STRUCTURE; ENZYME ASSAY; ENZYME BINDING; ENZYME STRUCTURE; ENZYME SUBUNIT; FATTY ACID SYNTHESIS; HYDROPHOBICITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN INTERACTION; STREPTOCOCCUS PNEUMONIAE;

BINDING, COMPETITIVE; CRYSTALLOGRAPHY, X-RAY; ENOYL-(ACYL-CARRIER-PROTEIN) REDUCTASE (NADH); KINETICS; MODELS, MOLECULAR; NAD; STREPTOCOCCUS PNEUMONIAE; THIAZOLES; UREA;

BACTERIA (MICROORGANISMS); PSEUDOMONAS AERUGINOSA; STREPTOCOCCUS PNEUMONIAE;

EID: 41649110512     PISSN: 09618368     EISSN: 1469896X     Source Type: Journal    
DOI: 10.1110/ps.073288808     Document Type: Article

References (44)

1. Altschul, S.F., Gish, W., Miller, W., Myers, E.W., and Lipman, D.J. 1990. Basic local alignment search tool. J. Mol. Biol. 215: 403-410.
2. Baldock, C., Rafferty, J.B., Sedelnikova, S.E., Baker, P.J., Stuitje, A.R., Slabas, A.R., Hawkes, T.R., and Rice, D.W. 1996. A mechanism of drug action revealed by structural studies of enoyl reductase. Science 274: 2107-2110.
3. Bartlett, J.G., Breiman, R.F., Mandell, L.A., and File Jr., T.M. 1998. Community-acquired pneumonia in adults: Guidelines for management. The Infectious Diseases Society of America. Clin. Infect. Dis. 26: 811-838.
4. Cohen, M.L. 1992. Epidemiology of drug resistance: Implications for a post-antimicrobial era. Science 257: 1050-1055.
5. Dessen, A., Quemard, A., Blanchard, J.S., Jacobs Jr., W.R., and Sacchettini, J.C. 1995. Crystal structure and function of the isoniazid target of Mycobacterium tuberculosis. Science 267: 1638-1641.
6. Emsley, P. and Cowtan, K. 2004. Coot: Model-building tools for molecular graphics. Acta Crystallogr. D Biol. Crystallogr. 60: 2126-2132.
7. Ha, J.Y., Min, J.Y., Lee, S.K., Kim, H.S., Kim do, J., Kim, K.H., Lee, H.H., Kim, H.K., Yoon, H.J., and Suh, S.W. 2006. Crystal structure of 2-nitropropane dioxygenase complexed with FMN and substrate. Identification of the catalytic base. J. Biol. Chem. 281: 18660-18667.
8. Heath, R.J. and Rock, C.O. 1995. Enoyl-acyl carrier protein reductase (fabI) plays a determinant role in completing cycles of fatty acid elongation in Escherichia coli. J. Biol. Chem. 270: 26538-26542.
9. Heath, R.J. and Rock, C.O. 1996. Regulation of fatty acid elongation and initiation by acyl-acyl carrier protein in Escherichia coli. J. Biol. Chem. 271: 1833-1836.
10. Heath, R.J. and Rock, C.O. 2000. A triclosan-resistant bacterial enzyme. Nature 406: 145-146.
11. Heath, R.J., Yu, Y.T., Shapiro, M.A., Olson, E., and Rock, C.O. 1998. Broad spectrum antimicrobial biocides target the FabI component of fatty acid synthesis. J. Biol. Chem. 273: 30316-30320.
12. Heath, R.J., Li, J., Roland, G.E., and Rock, C.O. 2000. Inhibition of the Staphylococcus aureus NADPH-dependent enoyl-acyl carrier protein reductase by triclosan and hexachlorophene. J. Biol. Chem. 275: 4654-4659.
13. Heath, R.J., White, S.W., and Rock, C.O. 2001. Lipid biosynthesis as a target for antibacterial agents. Prog. Lipid Res. 40: 467-497.
14. Heerding, D.A., Chan, G., DeWolf, W.E., Fosberry, A.P., Janson, C.A., Jaworski, D.D., McManus, E., Miller, W.H., Moore, T.D., Payne, D.J., et al. 2001. 1,4-Disubstituted imidazoles are potential antibacterial agents functioning as inhibitors of enoyl-acyl carrier protein reductase (FabI). Bioorg. Med. Chem. Lett. 11: 2061-2065.
15. Jenni, S., Leibundgut, M., Boehringer, D., Frick, C., Mikolasek, B., and Ban, N. 2007. Structure of fungal fatty acid synthase and implications for iterative substrate shuttling. Science 316: 254-261.
16. Johnson, C.N., Briles, D.E., Benjamin Jr., W.H., Hollingshead, S.K., and Waites, K.B. 2005. Relative fitness of fluoroquinolone-resistant Streptococcus pneumoniae. Emerg. Infect. Dis. 11: 814-820.
17. Kitagawa, H., Kumura, K., Takahata, S., Iida, M., and Atsumi, K. 2007a. 4-Pyridone derivatives as new inhibitors of bacterial enoyl-ACP reductase FabI. Bioorg. Med. Chem. Lett. 15: 1106-1116.
18. Kitagawa, H., Ozawa, T., Takahata, S., and Iida, M. 2007b. Phenylimidazole derivatives as new inhibitors of bacterial enoyl-ACP reductase FabK. Bioorg. Med. Chem. Lett. 17: 4982-4986.
19. Kitagawa, H., Ozawa, T., Takahata, S., Iida, M., Saito, J., and Yamada, M. 2007c. Phenylimidazole derivatives of 4-pyridone as dual inhibitors of bacterial enoyl-acyl carrier protein reductases FabI and FabK. J. Med. Chem. 50: 4710-4720.
20. Kwiek, J.J., Haystead, T.A., and Rudolph, J. 2004. Kinetic mechanism of quinone oxidoreductase 2 and its inhibition by the antimalarial quinolines. Biochemistry (Mosc.) 43: 4538-4547.
21. Laskowski, R.A., MacArthur, M.W., Moss, D.S., and Thornton, J.M. 1993. PROCHECK: A program to check the stereochemical quality of protein structures. J. Appl. Crystallogr. 26: 283-291.
22. Ling, L.L., Xian, J., Ali, S., Geng, B., Fan, J., Mills, D.M., Arvanites, A.C., Orgueira, H., Ashwell, M.A., Carmel, G., et al. 2004. Identification and characterization of inhibitors of bacterial enoyl-acyl carrier protein reductase. Antimicrob. Agents Chemother. 48: 1541-1547.
23. Maier, T., Jenni, S., and Ban, N. 2006. Architecture of mammalian fatty acid synthase at 4.5 Å resolution. Science 311: 1258-1262.
24. Marrakchi, H., Dewolf Jr., W.E., Quinn, C., West, J., Polizzi, B.J., So, C.Y., Holmes, D.J., Reed, S.L., Heath, R.J., Payne, D.J., et al. 2003. Characterization of Streptococcus pneumoniae enoyl-(acyl-carrier protein) reductase (FabK). Biochem. J. 370: 1055-1062.
25. Michalopoulos, I., Torrance, G.M., Gilbert, D.R., and Westhead, D.R. 2004. TOPS: An enhanced database of protein structural topology. Nucleic Acids Res. 32: D251-D254.
26. Murshudov, G.N., Vagin, A.A., and Dodson, E.J. 1997. Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53: 240-255.
27. Nagano, N., Orengo, C.A., and Thornton, J.M. 2002. One fold with many functions: The evolutionary relationships between TIM barrel families based on their sequences, structures and functions. J. Mol. Biol. 321: 741-765.
28. Payne, D.J., Miller, W.H., Berry, V., Brosky, J., Burgess, W.J., Chen, E., DeWolf Jr., W.E., Fosberry, A.P., Greenwood, R., Head, M.S., et al. 2002. Discovery of a novel and potent class of FabI-directed antibacterial agents. Antimicrob. Agents Chemother. 46: 3118-3124.
29. Potterton, L., McNicholas, S., Krissinel, E., Gruber, J., Cowtan, K., Emsley, P., Murshudov, G.N., Cohen, S., Perrakis, A., and Noble, M. 2004. Developments in the CCP4 molecular-graphics project. Acta Crystallogr. D Biol. Crystallogr. 60: 2288-2294.
30. Quemard, A., Sacchettini, J.C., Dessen, A., Vilcheze, C., Bittman, R., Jacobs Jr., W.R., and Blanchard, J.S. 1995. Enzymatic characterization of the target for isoniazid in Mycobacterium tuberculosis. Biochemistry 34: 8235-8241.
31. Rock, C.O. and Cronan, J.E. 1996. Escherichia coli as a model for the regulation of dissociable (type II) fatty acid biosynthesis. Biochim. Biophys. Acta 1302: 1-16.
32. Saito, J., Yamada, M., Watanabe, T., Kitagawa, H., and Takeuchi, Y. 2006. Crystallization and preliminary X-ray analysis of enoyl-acyl carrier protein reductase (FabK) from Streptococcus pneumoniae. Acta Crystallograph. F Struct. Biol. Cryst. Commun. 62: 576-578.
33. Seefeld, M.A., Miller, W.H., Newlander, K.A., Burgess, W.J., Payne, D.J., Rittenhouse, S.F., Moore, T.D., DeWolf Jr., W.E., Keller, P.M., Qiu, X., et al. 2001. Inhibitors of bacterial enoyl-acyl carrier protein reductase (FabI): 2,9-Disubstituted 1,2,3,4-tetrahydropyrido[3,4-b]indoles as potential antibacterial agents. Bioorg. Med. Chem. Lett. 11: 2241-2244.
34. Seefeld, M.A., Miller, W.H., Newlander, K.A., Burgess, W.J., DeWolf Jr., W.E., Elkins, P.A., Head, M.S., Jakas, D.R., Janson, C.A., Keller, P.M., et al. 2003. Indole naphthyridinones as inhibitors of bacterial enoyl-ACP reductases FabI and FabK. J. Med. Chem. 46: 1627-1635.
35. Slater-Radosti, C., Van Aller, G., Greenwood, R., Nicholas, R., Keller, P.M., DeWolf Jr., W.E., Fan, F., Payne, D.J., and Jaworski, D.D. 2001. Biochemical and genetic characterization of the action of triclosan on Staphylococcus aureus. J. Antimicrob. Chemother. 48: 1-6.
36. Takahata, S., Iida, M., Osaki, Y., Saito, J., Kitagawa, H., Ozawa, T., Yoshida, T., and Hoshiko, S. 2006. AG205, a novel agent directed against FabK of Streptococcus pneumoniae. Antimicrob. Agents Chemother. 50: 2869-2871.
37. Takahata, S., Iida, M., Yoshida, T., Kumura, K., Kitagawa, H., and Hoshiko, S. 2007. Discovery of 4-pyridone derivatives as specific inhibitors of enoyl-acyl carrier protein reductase (FabI) with antibacterial activity against Staphylococcus aureus. J. Antibiot. (Tokyo) 60: 123-128.
38. Terwilliger, T.C. 2000. Maximum-likelihood density modification. Acta Crystallogr. D Biol. Crystallogr. 56: 965-972.
39. Terwilliger, T.C. 2003a. Automated main-chain model building by template matching and iterative fragment extension. Acta Crystallogr. D Biol. Crystallogr. 59: 38-44.
40. Terwilliger, T.C. 2003b. Automated side-chain model building and sequence assignment by template matching. Acta Crystallogr. D Biol. Crystallogr. 59: 45-49.
41. Terwilliger, T.C. and Berendzen, J. 1999. Automated MAD and MIR structure solution. Acta Crystallogr. D Biol. Crystallogr. 55: 849-861.
42. Velazquez, I. and Pardo, J.P. 2001. Kinetic characterization of the rotenoneinsensitive internal NADH: Ubiquinone oxidoreductase of mitochondria from Saccharomyces cerevisiae. Arch. Biochem. Biophys. 389: 7-14.
43. Yum, J.H., Kim, C.K., Yong, D., Lee, K., Chong, Y., Kim, C.M., Kim, J.M., Ro, S., and Cho, J.M. 2007. In vitro activities of CG400549, a novel FabI inhibitor, against recent clinical staphylococcal isolates in Korea. Antimicrob. Agents Chemother. 51: 2591-2593.
44. Zheng, C.J., Sohn, M.J., and Kim, W.G. 2006. Atromentin and leucomelone, the first inhibitors specific to enoyl-ACP reductase (FabK) of Streptococcus pneumoniae. J. Antibiot. (Tokyo) 59: 808-812.